Skip Navigation Links
     
ARTICOLI ORIGINALI
  • Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, De Socio GV, Martinelli C, Gulminetti R, Maggi P, Orofino C, Vichi F, Di Biagio A, Bonfanti P, on behalf of CISAI Study Group.
    Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    BMC Inf Dis 2018; 18: 357.
  • Bagella P, De Socio GVL, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, FalascaK, Bonfanti P and Madeddu G on behalf of the C.I.S.A.I. Study Group, Italy.
    Durability, safety and efficacy of rilpivirine in clinical practice: results from the SCOLTA project.
    Infection and Drug Resistance, 2018; 11: 615-23.
  • Vitiello P, Taramasso L, Ricci E, Maggi P, Martinelli C, Gabrielli C, De Socio GV, Di Cristo V, Rusconi S, Falasca K, Menzaghi B, Tebini A, Di Biagio A.
    Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience.
    J Women Ageing 2019; 31: 176-188
  • Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A; CISAI Study Group.
    Weight Gain: A Possible Side Effect of All Antiretrovirals.
    Open Forum Infect Dis. 2017 Nov 3; 4(4):ofx239.
  • Taramasso L, Ricci E, Celesia BM, Bonfanti P, Quirino T, Squillace N, Nicolini LA, Maggi P, Martinelli C, De Socio GV, Di Biagio A; on behalf CISAI Study Group.
    Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
    Clin Res Hepatol Gastroenterol. 2017; 41: e76-e79.
  • Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, Rusconi S, Maggi P, Celesia BM, Cordier L, Vichi F, Calza L, Falasca K, Di Biagio A, Pellicanò GF, Bonfanti P, for the CISAI Study Group.
    Safety and tolerability of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
    PLoS ONE 12(6): e0179254.
  • De Socio GV, Ricci E, Maggi P, Parruti G, Celesia BM, Orofino G, Madeddu G, Martinelli C, Menzaghi B, Taramasso L, Bonfanti P, Pucci G, Schillaci G, for the CISAI study group.
    Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study.
    Journal of Hypertension 2017; 35: 409-16
  • Bonfanti P, Madeddu G, Gulminetti R, Squillace N, Orofino G, Vitiello P, Rusconi S, Celesia BM, Maggi P, Ricci E.
    Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.
    AIDS 2017; 31: 455-7
  • De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, Orofino G, Madeddu G, Martinelli C, Menzaghi B, Taramasso L, Penco G, Carenzi L, Franzetti M, Bonfanti P.
    Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY Study.
    Infection 2016; 44: 589-97
  • Nicolini LA, Menzaghi B, Ricci E, Martinelli C, Magni C, Maggi P, Celesia BM, Parruti G, Babudieri S, Bonfanti P, Falasca K, Vichi F, De Socio GV, Salomoni E, Di Biagio A, Quirino T.
    Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
    Eur J Gastroenterol Hepatol 2016; 28: 37-41.
  • Prinapori R, Ricci E, Menzaghi B, Borghi V, Maggi P, Martinelli C, Magni C, Parruti G, Bonfanti P, Mussini C, Di Biagio A; CISAI and Modena Cohort.
    Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy.
    AIDS. 2015; 29: 2061-2. doi: 10.1097/QAD.0000000000000785.
  • Madeddu G, De Socio GVL, Ricci E, Quirino T, Orofino G, Carenzi L, Franzetti M, Parruti G, Martinelli C, Vichi F, Penco G, Dentone C, Celesia BM, Maggi P, Libertone R, Bagella P, Di Biagio A, Bonfanti P.
    Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
    Int J Antimicr Agents 2015; 45: 289-94.
  • Taramasso L, Madeddu G, Ricci E, De Socio GVL, Menzaghi B, Orofino G, Passerini S, Franzetti M, Maggi P, Dentone C, Martinelli C, Celesia BM, Penco G, Libertone R, Quirino T, Bonfanti P, Di Biagio A, on behalf of the CISAI Study Group.
    Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
    Biomed Pharmacother 2015; 69: 233-236.
  • Menzaghi B, Ricci E, Vichi F, De Socio GV, Carenzi L, Martinelli C, Franzetti M, Orofino G, Madeddu G, Parruti G, Penco G, Grosso C, Di Biagio A, Bonfanti P, Quirino T; for the CISAI Study Group.
    Gender difference in HIV infection: is there a problem? Analysis from the SCOLTA Cohorts.
    Biomed Pharmacother 2014; 68: 385-90.
  • De Socio GV, Parruti G, Ricci E, Maggi P, Celesia BM, Penco G, Martinelli C, Franzetti M, Di Biagio A, Bonfanti P, Pucci G, Schillaci G; for the CISAI study group.
    Decreasing cardiovascular risk in HIV infection between 2005 and 2011.
    AIDS. 2014; 28: 609-612.
  • De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, Calza L, Orofino G, Carenzi L, Cecchini E, Madeddu G, Quirino T, Schillaci G. for the CISAI study group.
    Prevalence, awareness, treatment and control rate of hypertension in HIV-infected patients: the HIV-HY study.
    Am J Hypert 2014; 27: 222-228.
  • Di Biagio A, Ricci E, Viscoli C, Mesini A, menzaghi B, Carenzi L, Orofino G, Parruti G, Martinelli C, Madeddu G, De Socio GV, Franzetti M, Quirino T, Bonfanti P, on behalf of CISAI Group.
    The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment experienced HIV-1 infected patients.
    Curr HIV Res 2013; 11: 179-86
  • Schillaci G, Maggi P, Madeddu G, Pucci G, Mazzotta E, Penco G, Orofino G, Menzaghi B, Rusconi S, Carenzi L, Celesia BM, Martinelli C, Bonfanti P, De Socio GV; for the CISAI Study Group.
    Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study.
    J Hypertens 2013; 31: 560-7.
  • Menzaghi B, Ricci E, Carenzi L, Parruti G, Orofino G, Guastavigna M, Madeddu G, Maggi P, Di Biagio A, Corsi P, Penco G, De Socio G, Martinelli C, Vichi F, Celesia BM, Franzetti M, Grosso C, Molteni C, Bonfanti P, Quirino T.
    Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).
    Biomed Pharmacother 2013; 67: 293-8
  • Bonfanti P, De Socio GV, Ricci E, Orofino G, Martinelli C, Madeddu G, Antinori A, Vichi F, Penco G, Valsecchi L, Rusconi S, Menzaghi B, Pocaterra D, Quirino T.
    The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective study.
    Biomed Pharmacother 2012; 66: 348-53
  • Bonfanti P, Ricci E, De Socio G, Molteni C, Rusconi S, Vichi F, Penco G, Antinori A, Cordier L, Maggi P, Celesia BM, Grosso C, Quirino T.
    Low frequency of skin reactions in a cohort of patients on raltegravir.
    J Antimicrob Chemother 2012; 67: 1800-2
  • Madeddu G, Menzaghi B, Ricci E, Carenzi L, Martinelli C, di Biagio A, Parruti G, Orofino G, Mura MS, Bonfanti P; for the C.I.S.A.I Group.
    Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.
    AIDS 2012; 28: 2412-2415.
  • Parruti G, Polilli E, De Socio GV, Sozio F, Marconi P, Soddu V, Dalessandro M, Celesia BM, Pellicanò G, Madeddu G, Vecchiet J, Di Masi F, Mazzotta E, Ursini T, Martinelli C, Vitiello P, Bonfanti P, Nigro L, Mura MS, Antinori A, Ricci E, Manzoli L.
    Efficacy of 1998 vs 2006 first-line antiretroviral regimens for HIV infection: an ordinary clinics retrospective investigation.
    J Antivit Antiretrovir 2012; 4:32-37.
  • De Socio GVL, Ricci E, Bonfanti P, Quirino T, Schillaci G.
    Waist circumference and body mass index in HIV infection.
    HIV Med 2011; 12: 124-5.
  • Mazzotta E, Agostinone A, Rosso R, Di Biagio A, De Socio GV, Cappelletti A, Zicolella R, Polilli E, Bonfanti P, Di Matteo L, Manzoli L, Parruti G.
    Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study.
    J Bone Miner Metab 2011; 29: 383-8.
  • Giuntini R, Martinelli C, Ricci E, Vichi F, Gianelli E, Madeddu G, Abeli C, Palvarini L, Penco G, Marconi P, Grosso C, Pellicanò G, Bonfanti P, Quirino T for the C.I.S.A.I.
    Study Group (Italian Coordinators for the Study of Allergies and HIV Infection). Efficacy and safety of boosted and unboosted atazanavir-containing regimens in real life: results from a multicenter cohort study.
    HIV Med 2010; 11: 40-45.
  • Bonfanti P, De Socio GVL, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Madeddu G, Orofino G, Valsecchi L, Vitiello P, Menzaghi B, Magni C, Ricci E.
    Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study.
    Curr HIV Res 2010; 8 (2): 165-171.
  • De Socio GVL, Martinelli C, Ricci E, Orofino G, Valsecchi L, Vitiello P, Martinelli L, Quirino T, Maggi P, Bonfanti P, for the HERMES Study Group.
    Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES Study.
    Int J STD AIDS 2010; 21: 267-272.
  • De Socio GVL, Ricci E, Parruti G, Maggi P, Madeddu G, Bonfanit P, Quirino T.
    and biological age in HIV infection.
    Journal of Infection, 2010; 61: 428-30.
  • De Socio GV, Bonfanti P, Martinelli C, Ricci E, Pucci G, Marinoni M, Vitiello P, Menzaghi B, Rizzardini G, Schillaci G.
    Negative influence of HIV infection on day-night blood pressure variability.
    J Acquir Immune Defic Syndr 2010; 55: 356-60.
  • De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, Penco G, Gianelli E, Martinelli C, Carradori S, Quirino T, Rizzardini G; for the CISAI Study Group.
    Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: Results from the SCOLTA project.
    Biomed Pharmacother. 2008; 62: 16-20.
  • Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, Penco G, Rosella E, Miccolis S, Melzi S, Mura MS, Landonio S, Ricci E, Quirino T, for the CISAI Group.
    Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
    Biomed Pharmacother; 2008; 62: 6-11.
  • De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Sfara C, Madeddu G, Bonfanti P; for the CISAI study group.
    Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study.
    J Infect. 2008; 57: 33-40
  • Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G.
    HIV and Metabolic Syndrome: a comparison with the general population.
    J Acquir Immune Defic Syndr 2007; 45: 426-31.
  • Bonfanti P, Ricci E, de Socio G, Zeme D, Carradori S, Penco G, Parruti G, Grosso C, Madeddu G, Vichi F, Bini T, Martinelli C, Melzi S, Quirino T; CISAI Study Group.
    Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study.

    J Acquir Immune Defic Syndr. 2006 May;42(1):128-31.
  • Madeddu G, Quirino T, Carradori S, Ricci E, Grosso C, Penco G, De Socio G, Rosella E, Palvarini L, Marconi P, Melzi S, Mura MS e Bonfanti P per il gruppo CISAI.
    Renal toxicity in HIV-infected patients receiving HAART including tenofovir.
    Infez Med 2006;3: 125-134
  • Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, Magnani C, Quirino T; CISAI Group (Italian Coordinators for the Study of Allergies HIV Infection).
    An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (SurveillanceCohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.
    J Acquir Immune Defic Syndr. 2005; 39:317-20.
  • Bonfanti P, Ricci E, Penco G, Orofino G, Bini T, Sfara C, Miccolis S, Cristina G, Quirino T; CISAI Study Group.
    Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.
    AIDS. 2005 Sep 2;19(13):1433-4.
  • Quirino T, Bongiovanni M, Ricci E, Chebat E, Carradori S, Martinelli C, Valsecchi L, Landonio S, Bini T, Bonfanti P.
    “Hypothyroidism in HIV-infected patients who have or have not received HAART” Clin Infect Dis.
    2004;38(4):596-7.
  • Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, Vulpio L, Ricci E, Carrabba M, Vigevani G.M.
    “Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART”
    Biomed Pharmacother 2004; 58: 505-8.
  • Bonfanti P, Gulisano C, Ricci E, Timillero L, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Martinelli C, Faggion I, Landonio S, Quirino T, Vigevani GM.
    “Risk factors for lipodystrophy in the CISAI cohort”
    Biomed Pharmacother 2003; 57: 422-427
  • Landonio S, Quirino T, Pelucchi A, Magni C, Coen M, Porretta T, Faggion I, Bonfanti P, Vigevani GM.
    “Bilateral carotid stenosis in young female HIV-patient treated with HAART”
    AIDS 2002; 16: 2225 – 2227
  • Bonfanti P, Gabbuti A, Carradori S, Pusterla L, Parazzini F, Landonio S, Quirino T.
    “Osteonecrosis in protease inhibitor-treated patients”
    Orthopedics 2001; 24: 271 – 272
  • Bonfanti P, Landonio S, Ricci E, Martinelli E, Fortuna P, Faggion I, Quirino T.
    “Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy”
    J Acquir Immune Defic Syndr 2001; 27: 316 - 318
  • Bonfanti P, Ricci E, Landonio S, Valsecchi L, Timillero L, Faggion I, Quirino T for the CISAI study group.
    “Predictors of protease inhibitor-associated adverse events.”
    Biomed Pharmacother 2001; 55: 321 -323
  • Bonfanti P, Valsecchi L, Ricci E, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Cinelli R, Faggion I, Landonio S, Quirino T, Vigevani GM.
    “I diversi profili di tollerabilità degli Inibitori della proteasi: lo studio CISAI.
    Giorn It Mal Inf 2001; 7 (S2): S13- S17
  • Timillero L, Bonfanti P, Ricci E, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Cinelli R, Faggion I, Landonio S, Quirino T, Vigevani GM.
    “I fattori di rischio per lo sviluppo della lipodistrofia nella coorte CISAI”
    Giorn It Mal Inf 2001; 7 (S2): S65 – S67
  • Bonfanti P, Valsecchi L, Parazzini F,Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T.
    “Incidence of adverse reactions in HIV-patients treated with protease inhibitors: a cohort study”
    J Acquir Immune Defic Syndr 2000; 23: 236 – 245.
  • Quirino T, Niero F, Ricci E, Pusterla L, Carradori S, Gabbuti A, Iemoli E, Landonio S, Faggion I, Bonfanti P.
    “HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV infected patients.”
    Antivir Ther 2000; 5: 195-197
  • Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Ricci E, Martinelli C, Faggion I, Landonio S, Quirino T.
    “Relazione di causalità delle reazioni averse a farmaci: un’esperienza nell’utilizzo degli inibitori della proteasi di HIV”
    Clin Ter 2000; 151: 411-415
  • Vitiello P, Taramasso L, Ricci E, Maggi P, Martinelli C, Gabrielli C, Vittorio De Socio G, Di Cristo V, Rusconi S, Falasca K, Menzaghi B, Tebini A, Di Biagio A;
    "CISAI Study Group. Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience."
    J Women Aging. 2018 Jan 25:1-13.
  • Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A;
    "CISAI Study Group . Weight Gain: A Possible Side Effect of All Antiretrovirals."
    Open Forum Infect Dis. 2017 Nov 3;4(4):ofx239.
  • Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, Rusconi S, Maggi P, Celesia BM, Cordier L, Vichi F, Calza L, Falasca K, Di Biagio A, Pellicanò GF, Bonfanti P;
    "CISAI Study Group. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project."
    PLoS One. 2017 Jun 20;12(6):e0179254.
  • Taramasso L, Ricci E, Celesia BM, Bonfanti P, Quirino T, Squillace N, Nicolini LA, Maggi P, Martinelli C, De Socio GV, Di Biagio A;
    "On behalf CISAI Study Group. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?"
    Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):e76-e79.
  • Bonfanti P, Madeddu G, Gulminetti R, Squillace N, Orofino G, Vitiello P, Rusconi S, Celesia BM, Maggi P, Ricci E.
    "Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir."
    AIDS 2017; 31: 455-7
  • De Socio GV, Ricci E, Maggi P, Parruti G, Celesia BM, Orofino G, Madeddu G, Martinelli C, Menzaghi B, Taramasso L, Bonfanti P, Pucci G, Schillaci G
    "For the CISAI study group. Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study."
    Journal of Hypertension 2017; 35: 409-16
  • De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, Orofino G, Madeddu G, Martinelli C, Menzaghi B, Taramasso L, Penco G, Carenzi L, Franzetti M, Bonfanti P.
    "Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY Study."
    Infection 2016; 44: 589-97
  • Nicolini LA, Menzaghi B, Ricci E, Martinelli C, Magni C, Maggi P, Celesia BM, Parruti G, Babudieri S, Bonfanti P, Falasca K, Vichi F, De Socio GV, Salomoni E, Di Biagio A, Quirino T.
    "Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?"
    Eur J Gastroenterol Hepatol 2016; 28: 37-41.
  • Taramasso L, Ricci E, Cascio A, Valsecchi L, Menzaghi B, Squillace N, Maggi P, De Socio GV, Dentone C, Madeddu G, Pellicanò GF, Calza L, Angioni G, Bonfanti P, Di Biagio A.
    "CISAI Study Group. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)."
    AIDS Res Ther. 2019; 16: 21.
  • De Socio GV, Maggi P, Ricci E, Orofino G, Squillace N, Menzaghi B, Madeddu G, Di Biagio A, Francisci D, Bonfanti P, Vichi F, Schiaroli E, Santoro C, Guastavigna M, dell'Omo M.
    "Smoking habits in HIV-infected people from Italy: a cross-sectional analysis of the STOPSHIV cohort."
    AIDS Res Hum Retroviruses 2019.
  • Di Biagio A, Bonfanti P, Madeddu G, De Socio GV, Maggi P, Vichi F, Martinelli C, Menzaghi B, Orofino G, Squillace N, Ricci E, Acone B, Quirino T.
    "SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients."
    New Microbiol 2019; 42: 150-5.
  • Maggi P, Santoro CR, Nofri M, Ricci E, De Gennaro N, Bellacosa C, Schiaroli E, Orofino G, Menzaghi B, Di Biagio A, Squillace N, Francisci D, Vichi F, Molteni C, Bonfanti P, Gaeta GB, De Socio GV.
    "Clusterization of co-morbidities and multimorbidities among persons living with HIV: a cross-sectional study."
    BMC Inf Dis 2019; 19: 555.
  • Bagella P, Squillace N, Ricci E, Gulminetti R, De Socio GV, Taramasso L, Pellicanò G, Menzaghi B, Celesia BM, Dentone C, Orofino G, Bonfanti P, Madeddu G.
    "Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project."
    Infection and Drug Resistance 2019; 12: 1385-91.
CHI SIAMO
Gestisci preferenze cookie
FONDAZIONE A.S.I.A. ONLUS  /  VIA GARIBALDI, 13  /  20090 BUCCINASCO (MI)  /  P.IVA 05087350962
POWERED BY HEALTHROPY
Cookie policy
Privacy policy